Pediatrics
Showing 1-7 of 7 Results
-
Bing Wang
Postdoctoral Scholar, Stem Cell Transplantation
BioMy academic training and research experience have equipped me with multidisciplinary skills and knowledge of molecular biology and immunology.
I led two projects when I was an undergraduate, in which I got primary academic learning. My team member and I investigated the bacteria content in drinking water from two types of machines that are commonly used in colleges under the guidance of our experimental microbiology teacher Zhihong Zhong. Secondly, we produced a hybridoma cell line secreting monoclonal antibody against the core antigen of the hepatitis C virus (HCV) to develop an ELISA kit for the detection of HCV under the guidance of Dr. Rushi Liu and Minjing Liao.
Thereafter, as a Ph. D. candidate at Xiaoming Feng’s lab, my research primarily focused on understanding the biology of regulatory T cells (Treg) and CD11c+ myeloid cells using cutting-edge single-cell sequencing and conditional knockout mice under healthy and disease conditions. We first revealed the heterogeneity and bifurcated differentiation pathway of human Tregs from normal donors and transplanted patients at the single-cell transcriptome level. A subsequent first and corresponding author publication identified a key innate responsive protein in CD11c+ alveolar macrophages, NRP2, that protects mice from lung injury via promoting the phagocytosis of neutrophils. I also participated in two projects regarding the role of a serine/threonine kinase, LKB1, in mice CD11c+ dendritic cells from lymphoid tissues and adipose tissue with diet-induced obesity. These academic experiences guided me into a strong passion and independent capacities for biomedical studies.
For my postdoctoral training, I will focus on developing Treg therapies and genetic stem cell therapy to cure patients with IPEX syndrome (a severe autoimmune disease) at preclinical and clinical stages, and other immune disorders. My sponsor Dr. Rosa Bacchetta is a well-known leader in treating IPEX patients and developing Treg therapies. My co-mentor Dr. Maria Grazia Roncarolo is a well-recognized pediatric immunologist and also one of the pioneers in the stem cell and gene therapy field, who discovered the type 1 regulatory T cells or Tr1 cells and translate the scientific discoveries into novel Treg therapies. Both of them have an excellent record of training postdoctoral fellows. The proposed projects will provide me with great opportunities in cutting-edge technology and translational research and outline a set of career development including grant writing, public presentation, and lab management, which will enhance my ability to become an independent investigator and help me to reach my goal of developing efficient and safe Treg therapies for a wide range of immune disorders and associated human diseases. -
Wenjun Wang
Postdoctoral Scholar, Stem Cell Transplantation
Current Research and Scholarly InterestsMy postdoctoral research focuses on investigating novel therapy for childhood leukemias.
-
Yidan Wang
Postdoctoral Scholar, Neonatal and Developmental Medicine
BioI joined Dr. John Benjamin’s lab to study the heterogeneity of neutrophils across developmental stages and during bronchopulmonary dysplasia (BPD). My research focuses on characterizing neutrophil subsets and investigating the contributions of distinct neutrophil subsets to the development of BPD.
My predoctoral training was completed at Northwestern University under the co-mentorship of Dr. Harris Perlman and Dr. Deborah Winter. I studied the heterogeneity and functions of monocyte-lineage cells and macrophages in mouse synovial tissue under both steady-state and inflammatory arthritis conditions. -
Mulate Zerihun Workeneh
Postdoctoral Scholar, Critical Care
BioDr. Mulate Zerihun Workeneh is a Postdoctoral Scholar in Dr. Bereketeab Haileselassie’s laboratory in the Department of Pediatrics at Stanford University School of Medicine. He earned a Ph.D. in Medical Sciences from the Azrieli Faculty of Medicine at Bar-Ilan University, Israel, where he developed peptide therapeutics that target mitochondrial protein-protein interactions involved in cardiovascular disease. Dr. Workeneh’s research uses medicinal chemistry, chemical biology, peptide engineering, computational modeling and mitochondrial biology to understand how the disease occurs and to develop new ways to treat it. During his doctoral training, he designed and evaluated novel linear and macrocyclic peptide inhibitors that alter mitochondrial dynamics to mitigate mitochondrial dysfunction and cardiovascular injury. His work at Stanford is focused on defining the role of mitochondrial dynamics in endothelial dysfunction in sepsis and multiple organ dysfunction syndrome (MODS). He is working to develop peptide-based therapeutics that maintain mitochondrial function, improve vascular health and prevent organ failure in critically ill patients by integrating approaches in chemical biology, molecular and cellular biology, and translational drug discovery. Dr. Workeneh has publications in leading medicinal chemistry, pharmacology, and mitochondrial biology journals and is an inventor on patents related to mitochondrial protein-protein interaction inhibitors. His goal is to translate advances in mitochondrial biology into first-in-class therapeutics for cardiovascular disease, sepsis, and other disorders linked to mitochondrial dysfunction. He is excited to work across disciplines at Stanford to help push biomedical research forward.
